Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Jonathan M. Loree(University of British Columbia), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Van K. Morris(The University of Texas MD Anderson Cancer Center), Arvind Dasari(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Mark J. Routbort(The University of Texas MD Anderson Cancer Center), Russell R. Broaddus(University of North Carolina at Chapel Hill), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), David G. Menter(The University of Texas MD Anderson Cancer Center), Yusha Liu(Rice University), Kenna Shaw(Center for Personalized Cancer Treatment), Rajyalakshmi Luthra, Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Allan Andresson Lima Pereira(The University of Texas MD Anderson Cancer Center), Michael Lam(The University of Texas MD Anderson Cancer Center), Shailesh Advani(The University of Texas MD Anderson Cancer Center), Alexandra N. Willauer(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Jeffrey S. Morris(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University)
Cited by 318
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882